Your browser doesn't support javascript.
loading
Passive Prophylactic Administration with a Single Dose of Anti-Fel d 1 Monoclonal Antibodies REGN1908-1909 in Cat Allergen-induced Allergic Rhinitis: A Randomized, Double-Blind, Placebo-controlled Clinical Trial.
Shamji, Mohamed H; Singh, Iesha; Layhadi, Janice A; Ito, Constance; Karamani, Angeliki; Kouser, Lubna; Sharif, Hanisah; Tang, Jiaqian; Handijiev, Sava; Parkin, Rebecca V; Durham, Stephen R; Kostic, Ana; Orengo, Jamie M; DeVeaux, Michelle; Kamal, Mohamed; Stahl, Neil; Yancopoulos, George D; Wang, Claire Q; Radin, Allen R.
Affiliation
  • Shamji MH; Immunomodulation and Tolerance Group, Allergy and Clinical Immunology, Inflammation, Repair and Development, Medical Research Center-Asthma United Kingdom Centre in Allergic Mechanisms of Asthma, National Heart and Lung Institute, Imperial College London, London, United Kingdom; and.
  • Singh I; Immunomodulation and Tolerance Group, Allergy and Clinical Immunology, Inflammation, Repair and Development, Medical Research Center-Asthma United Kingdom Centre in Allergic Mechanisms of Asthma, National Heart and Lung Institute, Imperial College London, London, United Kingdom; and.
  • Layhadi JA; Immunomodulation and Tolerance Group, Allergy and Clinical Immunology, Inflammation, Repair and Development, Medical Research Center-Asthma United Kingdom Centre in Allergic Mechanisms of Asthma, National Heart and Lung Institute, Imperial College London, London, United Kingdom; and.
  • Ito C; Immunomodulation and Tolerance Group, Allergy and Clinical Immunology, Inflammation, Repair and Development, Medical Research Center-Asthma United Kingdom Centre in Allergic Mechanisms of Asthma, National Heart and Lung Institute, Imperial College London, London, United Kingdom; and.
  • Karamani A; Immunomodulation and Tolerance Group, Allergy and Clinical Immunology, Inflammation, Repair and Development, Medical Research Center-Asthma United Kingdom Centre in Allergic Mechanisms of Asthma, National Heart and Lung Institute, Imperial College London, London, United Kingdom; and.
  • Kouser L; Immunomodulation and Tolerance Group, Allergy and Clinical Immunology, Inflammation, Repair and Development, Medical Research Center-Asthma United Kingdom Centre in Allergic Mechanisms of Asthma, National Heart and Lung Institute, Imperial College London, London, United Kingdom; and.
  • Sharif H; Immunomodulation and Tolerance Group, Allergy and Clinical Immunology, Inflammation, Repair and Development, Medical Research Center-Asthma United Kingdom Centre in Allergic Mechanisms of Asthma, National Heart and Lung Institute, Imperial College London, London, United Kingdom; and.
  • Tang J; Immunomodulation and Tolerance Group, Allergy and Clinical Immunology, Inflammation, Repair and Development, Medical Research Center-Asthma United Kingdom Centre in Allergic Mechanisms of Asthma, National Heart and Lung Institute, Imperial College London, London, United Kingdom; and.
  • Handijiev S; Immunomodulation and Tolerance Group, Allergy and Clinical Immunology, Inflammation, Repair and Development, Medical Research Center-Asthma United Kingdom Centre in Allergic Mechanisms of Asthma, National Heart and Lung Institute, Imperial College London, London, United Kingdom; and.
  • Parkin RV; Immunomodulation and Tolerance Group, Allergy and Clinical Immunology, Inflammation, Repair and Development, Medical Research Center-Asthma United Kingdom Centre in Allergic Mechanisms of Asthma, National Heart and Lung Institute, Imperial College London, London, United Kingdom; and.
  • Durham SR; Immunomodulation and Tolerance Group, Allergy and Clinical Immunology, Inflammation, Repair and Development, Medical Research Center-Asthma United Kingdom Centre in Allergic Mechanisms of Asthma, National Heart and Lung Institute, Imperial College London, London, United Kingdom; and.
  • Kostic A; Regeneron Pharmaceuticals, Inc., Tarrytown, New York.
  • Orengo JM; Regeneron Pharmaceuticals, Inc., Tarrytown, New York.
  • DeVeaux M; Regeneron Pharmaceuticals, Inc., Tarrytown, New York.
  • Kamal M; Regeneron Pharmaceuticals, Inc., Tarrytown, New York.
  • Stahl N; Regeneron Pharmaceuticals, Inc., Tarrytown, New York.
  • Yancopoulos GD; Regeneron Pharmaceuticals, Inc., Tarrytown, New York.
  • Wang CQ; Regeneron Pharmaceuticals, Inc., Tarrytown, New York.
  • Radin AR; Regeneron Pharmaceuticals, Inc., Tarrytown, New York.
Am J Respir Crit Care Med ; 204(1): 23-33, 2021 07 01.
Article de En | MEDLINE | ID: mdl-33651675
Sujet(s)
Mots clés
Texte intégral
Ajouter à My VHL
Imprimer
XML
PubMed Links
Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Allergènes / Glycoprotéines / Chats / Antiallergiques / Rhinite allergique / Facteurs immunologiques / Anticorps monoclonaux Type d'étude: Clinical_trials / Etiology_studies Limites: Adult / Aged / Aged80 / Animals / Female / Humans / Male / Middle aged Langue: En Journal: Am J Respir Crit Care Med Sujet du journal: TERAPIA INTENSIVA Année: 2021 Type de document: Article
Texte intégral
Ajouter à My VHL
Imprimer
XML
PubMed Links
Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Allergènes / Glycoprotéines / Chats / Antiallergiques / Rhinite allergique / Facteurs immunologiques / Anticorps monoclonaux Type d'étude: Clinical_trials / Etiology_studies Limites: Adult / Aged / Aged80 / Animals / Female / Humans / Male / Middle aged Langue: En Journal: Am J Respir Crit Care Med Sujet du journal: TERAPIA INTENSIVA Année: 2021 Type de document: Article